Recombinant Protein Therapeutics
Fusion Proteins & Beyond
January 21-22, 2013
Day 1| Day 2 | Download Pipeline 3 Brochure
TUESDAY, JANUARY 22
7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee
7:45 Chairperson’s Remarks
Arieh Gertler, Ph.D., Professor, Biochemistry, Nutrition and Food Science, Hebrew University of Jerusalem
7:50 Recombinant Target-Binding Human Serum Albumin-Mediated Delivery of Long-Lasting Drugs
Zhiyu Li, Ph.D., Assistant Professor, Pharmaceutical Sciences, Philadelphia College of Pharmacy
Based on the unique protein structure, novel recombinant human serum albumins (HSA) with target-binding function, such as the recognition of αvβ3 integrin or HER2 cancer biomarkers, have been designed, constructed, and characterized in our lab. These target-binding albumins maintain the biological and biochemical properties of wild type albumins, especially the strong long chain fatty acid binding capability. Therefore, target-binding albumin is capable of forming stable non-covalent complex with fatty acid-conjugated small molecules, peptidomimetic, and nucleic acid drugs; consequently, facilitates cell-targeted delivery, prolonged drug stability, and enhanced drug uptake. More important, this system can co-deliver two or more different drugs to the same designated cell. We have tested the feasibility of co-delivering p53-activating peptide and methotrexate to augment cancer cell apoptosis.
8:20 FynomAbs: Taking Antibodies to the Next Level
Simon Brack, Ph.D., Director, Discovery Research, Covagen AG - Biography
Fynomers represent a new class of binding molecules based on the Fyn SH3 domain. Their intrinsic drug-like properties and high versatility make Fynomers ideal building blocks for the generation of innovative multispecific formats. We will show novel bispecific Fynomer-antibody fusion formats (FynomAbs) and provide examples of their excellent in vitro and in vivo activity.
8:50 XTEN – A Biodegradable Protein Polymer Alternative to PEG
Volker Schellenberger, Ph.D., CEO & President, Discovery, Amunix - Biography
Amunix’s half-life extension technology is based on XTEN, an unstructured protein-based polymer with PEG-like properties. XTEN, however, offers multiple advantages over PEG. XTEN can be expressed as recombinant fusions with polypeptides and proteins of interest. The inclusion of thiol and/or amino groups in pre-defined locations enables the generation bispecific XTENylated products with controlled valency. Purified XTEN polymer used for conjugation is monodisperse, allowing for efficient process development and monitoring by mass spec.
9:20 Engineered Affibody Molecules in Mono- and Bi-Specific Format Combined with Half-Life Extension for Therapy and Imaging
Joachim Feldwisch, Ph.D., Director, Pre-Clinical Development, Research, Affibody AB - Biography
Affibody molecules are small scaffold proteins with rapid in vivo kinetics making them ideal for clinical imaging studies. Data from a recent clinical trial confirmed the superior format for tumor targeting and in vivo receptor status determination. The kinetics of Affibody molecules and other small biotherapeutics can be extended up to several weeks by applying Affibody’s Albumod technology based on an albumin binding domain as a fusion partner. Bispecific targeting of growth factor receptors and recent progress will be presented.
9:50 Label-Free, Immobilization-Free Analysis of Biomolecular Interactions by Light ScatteringDaniel Some, Ph.D., Principal Scientist, Wyatt Technology CorporationComposition-Gradient Multi-Angle Static Light Scattering (CG-MALS) determines the affinity and absolute stoichiometry of protein-protein and other biomolecular interactions in solution without tagging or surface immobilization. The real power of CG-MALS lies in its capability for analyzing complex interactions: multivalent, multi-epitope and cooperative binding phenomena are all amenable to quantitative characterization, as are simultaneous self- and hetero-association, all with minimal method development, consumables and sample prep. Examples of basic and complex interactions will be presented.
10:05 Coffee Break in the Exhibit Hall with Poster Viewing
10:45 Novel Superactive Leptin Antagonists and Their Potential Application for Research and Treatment of Pathologies
Arieh Gertler, Ph.D., Professor, Biochemistry, Nutrition and Food Science, Hebrew University of Jerusalem - Biography
Using bidimensional hydrophobic cluster analysis we developed leptin antagonists (L39A/D40A/F41A muteins). Subsequently using random mutagenesis and selection by yeast surface display we increased dramatically their affinity toward leptin receptors by additional mutation (D23L). Those modified proteins are potent reagents for research of metabolic syndrome and T2DM and eventually for therapy of various pathologies enhanced by leptin, such as autoimmune diseases, cancer and certain forms of cachexia.
11:15 Development and Optimization of D-Protein Antagonists of VEGF-A Using ForteBio's Octet PlatformJohn Kenney, Ph.D., President, Antibody Solutions Employing ForteBio's BLI technology platform, designed libraries based upon the B1 domain of streptococcal protein G were used to develop high affinity D-protein antagonists for VEGF-A. The D-protein antagonists block the interaction of VEGF-A with VEGFR2 receptor and inhibit VEGF-A-induced proliferation of human umbilical vein endothelial cells. The D-protein antagonists are less immunogenic and more stable in vivo compared to their L-protein counterparts.
11:45 Mineral-Targeting Recombinant Alkaline Phosphatase
José Luis Millán, Ph.D., Professor, Sanford Children's Health Research Center, Sanford-Medical Research Institute - Biography
Hypophosphatasia (HPP) is the inborn error of metabolism characterized by deficiency of alkaline phosphatase activity, leading to rickets or osteomalacia. We produced a recombinant alkaline phosphatase with high affinity for bone mineral via the addition of a C-terminal ceca-aspartate sequence. This mineral-targentin alkaline phosphatase prevented all the manifestation of hypophosphatasia in a murine model of the disease including the seizures, rickets and osteomalacia. Ongoing clinical trials are proving successful.
12:15 pm Lanthionine-Stabilized, Receptor Specific, Agonist Peptides for G-Protein Coupled Receptors
Gert Moll, Ph.D., CSO, Lanthio Pharma - Biography
Lanthionines are thioether-linked amino acids. The introduction of lanthionines in peptide therapeutics strongly enhances their stability and receptor specificity. This is illustrated with a highly novel angiotensin type 2 receptor agonist, termed LP2, with high in vivo efficacy for treating right ventricle hypertrophy. It is also illustrated with PanCyte, which acts via the Mas receptor leading to high therapeutic efficacy in animal models of Acute Respiratory Distress Syndrome and heart failure.
12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
2:00 BuzZ Session A (Please visit our website for an up-to-date listing of topics.)
2:45 Refreshment Break in the Exhibit Hall with Poster Awards
3:30 BuzZ Session B (Please visit our website for an up-to-date listing of topics.)
4:15 End of Conference
Day 1| Day 2 | Download Pipeline 3 Brochure